Birdwatch Note
2023-03-16 18:47:41 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Ivermectin and Hydroxychloroquine have been shown not to have efficacy in COVID-19 based on randomized controlled trials. There is nothing in federal law that prohibits a preventative measure from being authorized for emergency use because a treatment is available https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://www.sciencedirect.com/science/article/pii/S1477893921001769 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/full https://apnews.com/article/fact-check-covid-vaccines-emergency-use-873264912929
Written by 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1634345437560750080
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1636439109156651012
- noteId - 1636439109156651012
- participantId -
- noteAuthorParticipantId - 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31 Participant Details
- createdAtMillis - 1678992461848
- tweetId - 1634345437560750080
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Ivermectin and Hydroxychloroquine have been shown not to have efficacy in COVID-19 based on randomized controlled trials. There is nothing in federal law that prohibits a preventative measure from being authorized for emergency use because a treatment is available https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub3/full https://www.sciencedirect.com/science/article/pii/S1477893921001769 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013587.pub2/full https://apnews.com/article/fact-check-covid-vaccines-emergency-use-873264912929
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-03-16 18:47:41 UTC (1678992461848) |
1969-12-31 23:59:59 UTC (-1) |
2023-03-17 06:38:20 UTC (1679035100346) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-03-16 19:17:05 -0500 | Rating Details | |
2023-03-16 17:49:45 -0500 | Rating Details | |
2023-03-16 17:42:54 -0500 | Rating Details | |
2023-03-16 17:25:42 -0500 | Rating Details | |
2023-03-16 16:43:22 -0500 | Rating Details | |
2023-03-16 16:43:07 -0500 | Rating Details | |
2023-03-16 16:33:16 -0500 | Rating Details | |
2023-03-16 16:30:57 -0500 | Rating Details | |
2023-03-16 16:06:54 -0500 | Rating Details | |
2023-03-16 15:53:22 -0500 | Rating Details | |
2023-03-16 15:48:44 -0500 | Rating Details | |
2023-03-16 15:38:42 -0500 | Rating Details | |
2023-03-16 15:34:25 -0500 | Rating Details | |
2023-03-16 15:02:02 -0500 | Rating Details | |
2023-03-16 14:36:25 -0500 | Rating Details | |
2023-03-16 14:34:24 -0500 | Rating Details | |
2023-03-16 14:32:22 -0500 | Rating Details | |
2023-03-16 14:27:39 -0500 | Rating Details | |
2023-03-16 14:23:20 -0500 | Rating Details | |
2023-03-16 13:56:17 -0500 | Rating Details | |
2023-03-16 13:51:27 -0500 | Rating Details | |
2023-03-17 17:40:41 -0500 | Rating Details | |
2023-03-17 17:22:46 -0500 | Rating Details | |
2023-03-17 16:53:05 -0500 | Rating Details | |
2023-03-17 16:29:45 -0500 | Rating Details | |
2023-03-17 15:30:54 -0500 | Rating Details | |
2023-03-17 14:52:52 -0500 | Rating Details | |
2023-03-17 14:18:31 -0500 | Rating Details | |
2023-03-17 13:19:49 -0500 | Rating Details | |
2023-03-17 12:56:18 -0500 | Rating Details | |
2023-03-17 12:37:57 -0500 | Rating Details | |
2023-03-17 12:19:22 -0500 | Rating Details | |
2023-03-17 11:50:47 -0500 | Rating Details | |
2023-03-17 08:59:51 -0500 | Rating Details | |
2023-03-17 07:28:50 -0500 | Rating Details | |
2023-03-17 05:58:59 -0500 | Rating Details | |
2023-03-17 04:00:40 -0500 | Rating Details | |
2023-03-17 03:56:08 -0500 | Rating Details | |
2023-03-17 02:22:07 -0500 | Rating Details | |
2023-03-16 23:45:12 -0500 | Rating Details | |
2023-03-16 21:09:09 -0500 | Rating Details | |
2023-03-16 20:58:37 -0500 | Rating Details | |
2023-03-16 20:06:57 -0500 | Rating Details | |
2023-03-16 20:05:10 -0500 | Rating Details | |
2023-03-16 19:37:36 -0500 | Rating Details | |
2023-03-18 14:07:20 -0500 | Rating Details | |
2023-03-18 12:43:38 -0500 | Rating Details | |
2023-03-18 11:05:56 -0500 | Rating Details | |
2023-03-20 11:40:51 -0500 | Rating Details | |
2023-03-21 18:57:36 -0500 | Rating Details | |
2023-03-22 11:19:32 -0500 | Rating Details | |
2023-03-27 18:17:16 -0500 | Rating Details | |
2023-05-19 09:53:26 -0500 | Rating Details | |
2023-04-21 08:25:19 -0500 | Rating Details | |
2023-03-16 14:36:25 -0500 | Rating Details | |
2023-03-18 12:43:38 -0500 | Rating Details | |
2023-03-18 11:05:56 -0500 | Rating Details | |
2023-03-20 11:40:51 -0500 | Rating Details | |
2023-03-16 15:48:44 -0500 | Rating Details | |
2023-03-17 16:53:05 -0500 | Rating Details | |
2023-03-16 16:43:07 -0500 | Rating Details | |
2023-03-17 11:50:47 -0500 | Rating Details | |
2023-03-16 16:06:54 -0500 | Rating Details | |
2023-03-17 12:37:57 -0500 | Rating Details | |
2023-03-16 19:17:05 -0500 | Rating Details | |
2023-03-17 03:56:08 -0500 | Rating Details | |
2023-03-18 14:07:20 -0500 | Rating Details | |
2023-03-16 23:45:12 -0500 | Rating Details | |
2023-03-16 16:43:22 -0500 | Rating Details | |
2023-03-17 12:19:22 -0500 | Rating Details | |
2023-03-16 14:23:20 -0500 | Rating Details | |
2023-03-16 20:58:37 -0500 | Rating Details | |
2023-03-16 14:34:24 -0500 | Rating Details | |
2023-03-17 12:56:18 -0500 | Rating Details | |
2023-03-16 20:05:10 -0500 | Rating Details | |
2023-03-17 08:59:51 -0500 | Rating Details | |
2023-03-21 18:57:36 -0500 | Rating Details | |
2023-03-17 05:58:59 -0500 | Rating Details | |
2023-03-17 07:28:50 -0500 | Rating Details | |
2023-03-16 17:49:45 -0500 | Rating Details | |
2023-03-22 11:19:32 -0500 | Rating Details | |
2023-03-17 14:18:31 -0500 | Rating Details | |
2023-04-21 08:25:19 -0500 | Rating Details | |
2023-03-16 15:38:42 -0500 | Rating Details | |
2023-03-16 13:56:17 -0500 | Rating Details | |
2023-03-16 13:51:27 -0500 | Rating Details | |
2023-03-16 20:06:57 -0500 | Rating Details | |
2023-05-19 09:53:26 -0500 | Rating Details | |
2023-03-17 14:52:52 -0500 | Rating Details | |
2023-03-16 16:33:16 -0500 | Rating Details | |
2023-03-16 15:02:02 -0500 | Rating Details | |
2023-03-17 17:22:46 -0500 | Rating Details | |
2023-03-18 03:46:24 -0500 | Rating Details | |
2023-03-17 17:40:41 -0500 | Rating Details | |
2023-03-16 15:34:25 -0500 | Rating Details | |
2023-03-17 15:30:54 -0500 | Rating Details | |
2023-03-17 16:29:45 -0500 | Rating Details | |
2023-03-16 17:25:42 -0500 | Rating Details | |
2023-03-17 04:00:40 -0500 | Rating Details | |
2023-03-27 18:17:16 -0500 | Rating Details | |
2023-03-16 14:27:39 -0500 | Rating Details | |
2023-03-16 16:30:57 -0500 | Rating Details | |
2023-03-17 13:19:49 -0500 | Rating Details | |
2023-03-16 21:09:09 -0500 | Rating Details | |
2023-03-17 02:22:07 -0500 | Rating Details | |
2023-03-16 15:53:22 -0500 | Rating Details | |
2023-03-16 19:37:36 -0500 | Rating Details | |
2023-07-23 03:47:28 -0500 | Rating Details |